Here are four things to know:
1. The company sold 7.5 million shares at $12, surpassing its goal of $87.2 million. The final amount raised could reach more than $100 million.
2. It is the third Bay Area life sciences company to go public this year, after Audentes Therapeutics and Corvus Pharmaceuticals.
3. Though the company has raised $67 million since it was founded 15 years ago, it has no revenue. It has an accumulated deficit of $39.1 million.
4. Its primary stakeholders include Johnson & Johnson, Pharmstandard International and R.A. Capital Healthcare Fund.
More articles on gastroenterology and endoscopy:
Madrigal Pharmaceuticals names Dr. Richard Levy to board: 4 points
Finger Lakes Gastroenterology joins FLH Medical: 3 notes
HCSC, Florida Blue now cover Exact Sciences’ Cologuard: 5 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
